Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence a Phase I/IIa trial of its investigational ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company specializing in RNA interference (RNAi) technology with a market capitalization of $2.73 billion, stands at a critical ...

2025年1月20日，Arrowhead Pharmaceuticals宣布，美国食品药品监督管理局（FDA）已正式受理plozasiran（商品名：Tryngolza）用于治疗家族性乳糜微粒血症综合征（FCS）的新药申请（NDA），并设定处方药使用者付费法案（PDUFA）行动日期为2025年11月18日。FDA目前不计划召开咨询委员会会议。

“ARO-INHBE is an important program for Arrowhead that complements our strategic focus on developing and commercializing important RNAi-based therapies for cardiometabolic diseases ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

Arrowhead also intends to submit applications ... is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which ...

Arrowhead (ARWR) Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference RNAi therapeutic being ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss ...

PASADENA, Calif., December 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s ...